UPDATE: Baird Downgrades Progenity Inc. (PROG) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to UPDATE: Baird Downgrades Progenity Inc. (PROG) to Neutral
June 2, 2021 7:00 AM EDT
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations from more than $180 million currently to targeted operating expenses of ~$50 million in 2022
Continuing to seek opportunities to generate non-dilutive capital through partnerships and strategic alternatives for non-core assets, including Avero Diagnostics, which may help fund the company
Focused on delivering on exciting 2021 and 2022 R&D pipeline with the PreecludiaTM test, gastrointestinal (GI) health, and oral biopharmaceutical program milestones   Management to host webcast... More
June 2, 2021 7:00 AM EDT
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations from more than $180 million currently to targeted operating expenses of ~$50 million in 2022
Continuing to seek opportunities to generate non-dilutive capital through partnerships and strategic alternatives for non-core assets, including Avero Diagnostics, which may help fund the company
Focused on delivering on exciting 2021 and 2022 R&D pipeline with the PreecludiaTM test, gastrointestinal (GI) health, and oral biopharmaceutical program milestones
  ... More
